Alexander J Lepak

List of Publications by Year in Descending Order

40 papers	734 citations	15 h-index	26 g-index
40 ext. papers	917 ext. citations	6.2 avg, IF	4.63 L-index

#	Paper	IF	Citations
40	Clinical utility of dual anterior nares and oropharynx MRSA screening polymerase chian reaction assay (PCR) for patients with suspected pneumonia. *Infection Control and Hospital Epidemiology*, **2021**, 1-3	2	1
39	Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel. *Clinical Infectious Diseases*, **2021**, 73, e1329-e1336	11.6	16
38	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. *American Journal of Health-System Pharmacy*, **2021**, 78, 2256-2264	2.2	0
37	Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic. *JAMA Internal Medicine*, **2021**, 181, 1399-1402	11.5	10
36	Letter to the Editor. *Clinical Infectious Diseases*, **2021**, 73, 1548	11.6	
35	Implementation of infection control measures to prevent healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2). *Infection Control and Hospital Epidemiology*, **2021**, 42, 229-232	2	5
34	COVID-19 in Health Care Personnel: Significance of Health Care Role, Contact History, and Symptoms in Those Who Test Positive for SARS-CoV-2 Infection. *Mayo Clinic Proceedings*, **2021**, 96, 2312-2322	6.4	3
33	Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia - ERRATUM.. *Infection Control and Hospital Epidemiology*, **2021**, 1	2	
32	Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	6
31	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 3023-3028	5.1	7
30	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	4
29	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	7
28	Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Academic Center in a Low-Prevalence Area of the United States. *Open Forum Infectious Diseases*, **2020**, 7, ofaa388	1	2
27	Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
26	Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	8
25	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against in an Model of Invasive Pulmonary Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	26
24	Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	15

23	WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing in the Neutropenic Mouse Pneumonia Model. *Antimicrobial Agents and Chemotherapy*, **2019**,	5.9	13
22	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	9
21	In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. *Diagnostic Microbiology and Infectious Disease*, **2019**, 93, 258-260	2.9	6
20	Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	45
19	The Wrong Frame of Mind. *New England Journal of Medicine*, **2018**, 378, 1716-1721	59.2	1
18	Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	6
17	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	36
16	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN). *Open Forum Infectious Diseases*, **2018**, 5, S426-S426	1	1
15	Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	38
14	Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	32
13	Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	51
12	Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	25
11	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	19
10	Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection. *Open Forum Infectious Diseases*, **2017**, 4, S73-S73	1	78
9	Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. *Current Treatment Options in Infectious Diseases*, **2017**, 9, 356-370	1	1
8	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	53
7	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 6390-6400	3.4	57
6	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4764-9	5.9	34

5	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). *Open Forum Infectious Diseases*, **2016**, 3,	1	1
4	In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1258-64	5.9	28
3	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1265-72	5.9	73
2	Antifungal PK/PD considerations in fungal pulmonary infections. *Seminars in Respiratory and Critical Care Medicine*, **2011**, 32, 783-94	3.9	13
1	Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact		1